Bevacizumab (Avastin)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Monoclonal antibody that inhibits angiogenesis by binding VEGF and preventing the interaction of VEGF with its receptors (Flt-1 and KDR) on the surface of endothelial cells.[1][2][3]
Route: IV
Extravasation: neutral

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Information about counterfeit bevacizumab

Patient drug information

History of changes in FDA indication

Breast cancer

  • 2/22/2008: Granted accelerated approval for use in combination with paclitaxel for the treatment of patients who have not received chemotherapy for metastatic HER2 negative breast cancer. (New disease entity)

Cervical cancer

Colorectal cancer

Glioblastoma

  • 5/5/2009: Granted accelerated approval as a single agent for patients with glioblastoma, with progressive disease following prior therapy. (New disease entity)

Hepatocellular carcinoma

  • 5/29/2020: Approved in combination with atezolizumab for patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy. (New disease entity)

Non-small cell lung cancer

Ovarian cancer

Renal cell carcinoma

  • 7/31/2009: Approved in combination with interferon alfa for the treatment of patients with metastatic renal cell carcinoma. (New disease entity)

Also known as

  • Generic name: rhuMab-VEGF
  • Brand names: Altuzan, Avastin, BevaciRel, Bevarest

References